Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, and Chad Cannon, PharmD, BCCCP, open a panel discussion highlighting specialty biologics and navigating challenges for biosimilar uptake.
Biosimilars Unveiled: Current Trends, Challenges, and Future Opportunities in the US Marketplace
Dr Humphreys drives a conversation scoping the biosimilar landscape and available treatment options.
The panel discusses the impact of interchangeability and value of switching studies in biosimilar adoption.
Dr. Cannon leads a conversation navigating the impact of payer coverage on the uptake of biosimilars.
The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.
The panel discusses the economic impact biosimilars have across different patient types.
The expert panel discusses the greater potential for private label biosimilars.
Dr. Cannon discusses payers and PBMs making decisions about biosimilars in the commercial sector.
The panel discusses how employer preferences influence the strategies and decisions of payers/PBMs.
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Dr. Tichy discusses unmet needs he deems crucial for the continued uptake of biosimilars.
The panel discusses ideal goals for biosimilar utilization.
The expert panel discuss future trends in the biosimilar space.
The expert panel discuss the importance of legislative support to continue innovations in the biosimilar space.
The panelists provide their closing thoughts, highlighting key considerations around biosimilar.
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
3
ATTR-CM Incidence, Prevalence Rose Sharply in the US
4
Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups
5